224 related articles for article (PubMed ID: 30087142)
1.
Ganaie AA; Beigh FH; Astone M; Ferrari MG; Maqbool R; Umbreen S; Parray AS; Siddique HR; Hussain T; Murugan P; Morrissey C; Koochekpour S; Deng Y; Konety BR; Hoeppner LH; Saleem M
Clin Cancer Res; 2018 Dec; 24(24):6421-6432. PubMed ID: 30087142
[TBL] [Abstract][Full Text] [Related]
2.
Umbreen S; Banday MM; Jamroze A; Mansini AP; Ganaie AA; Ferrari MG; Maqbool R; Beigh FH; Murugan P; Morrissey C; Corey E; Konety BR; Saleem M
Mol Cancer Ther; 2019 Nov; 18(11):2111-2123. PubMed ID: 31467179
[TBL] [Abstract][Full Text] [Related]
3. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
4. BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.
Siddique HR; Parray A; Zhong W; Karnes RJ; Bergstralh EJ; Koochekpour S; Rhim JS; Konety BR; Saleem M
PLoS One; 2013; 8(1):e52993. PubMed ID: 23308129
[TBL] [Abstract][Full Text] [Related]
5. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.
Siddique HR; Parray A; Tarapore RS; Wang L; Mukhtar H; Karnes RJ; Deng Y; Konety BR; Saleem M
PLoS One; 2013; 8(5):e60664. PubMed ID: 23671559
[TBL] [Abstract][Full Text] [Related]
6. ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.
Parray A; Siddique HR; Kuriger JK; Mishra SK; Rhim JS; Nelson HH; Aburatani H; Konety BR; Koochekpour S; Saleem M
Int J Cancer; 2014 Dec; 135(11):2493-506. PubMed ID: 24752651
[TBL] [Abstract][Full Text] [Related]
7. Identifying and treating ROBO1
Ferrari MG; Ganaie AA; Shabenah A; Mansini AP; Wang L; Murugan P; Davicioni E; Wang J; Deng Y; Hoeppner LH; Warlick CA; Konety BR; Saleem M
Prostate; 2020 Sep; 80(13):1045-1057. PubMed ID: 32687658
[TBL] [Abstract][Full Text] [Related]
8. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
Crea F; Duhagon Serrat MA; Hurt EM; Thomas SB; Danesi R; Farrar WL
Int J Cancer; 2011 Apr; 128(8):1946-54. PubMed ID: 20568112
[TBL] [Abstract][Full Text] [Related]
9. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O
Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945
[TBL] [Abstract][Full Text] [Related]
10. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis.
Luo HB; Li B; Yuan WG; Xu CR
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):730-735. PubMed ID: 26489630
[TBL] [Abstract][Full Text] [Related]
12. BMI‑1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor.
Yu J; Chen L; Bao Z; Liu Y; Liu G; Li F; Li L
Oncol Rep; 2020 May; 43(5):1630-1640. PubMed ID: 32323819
[TBL] [Abstract][Full Text] [Related]
13. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
14. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
15. Race-associated expression of MHC class I polypeptide-related sequence A (MICA) in prostate cancer.
Sakiyama MJ; Espinoza I; Reddy A; de Carlo F; Kumar A; Levenson AS; Bae S; Zhou X; Claudio PP; Lewin J; Manucha V; Pound CR; Vijayakumar S; Gomez CR
Exp Mol Pathol; 2019 Jun; 108():173-182. PubMed ID: 31004600
[TBL] [Abstract][Full Text] [Related]
16. BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance.
Ferretti R; Bhutkar A; McNamara MC; Lees JA
Genes Dev; 2016 Jan; 30(1):18-33. PubMed ID: 26679841
[TBL] [Abstract][Full Text] [Related]
17. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
18. Aberrantly elevated Bmi1 promotes cervical cancer tumorigenicity and tumor sphere formation via enhanced transcriptional regulation of Sox2 genes.
Xu R; Chen L; Yang WT
Oncol Rep; 2019 Aug; 42(2):688-696. PubMed ID: 31173263
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.
Bartucci M; Hussein MS; Huselid E; Flaherty K; Patrizii M; Laddha SV; Kui C; Bigos RA; Gilleran JA; El Ansary MMS; Awad MAM; Kimball SD; Augeri DJ; Sabaawy HE
Target Oncol; 2017 Aug; 12(4):449-462. PubMed ID: 28589491
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer.
Buechel M; Dey A; Dwivedi SKD; Crim A; Ding K; Zhang R; Mukherjee P; Moore KN; Cao L; Branstrom A; Weetall M; Baird J; Bhattacharya R
Mol Cancer Ther; 2018 Oct; 17(10):2136-2143. PubMed ID: 30026381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
